PTC Therapeutics Inc. diskutieren
PTC Therapeutics Inc.
WKN: A1W0MW / Symbol: PTCT / Name: PTC Therapeutics / Aktie / Biotechnologie & medizinische Forschung / Mid Cap /
63,00 €
1,61 %
PTC Therapeutics, Inc. (NASDAQ: PTCT) had its price target raised by analysts at Citigroup Inc. from $26.00 to $32.00. They now have a "sell" rating on the stock.
Ratings data for PTCT provided by MarketBeat
PTC Therapeutics, Inc. (NASDAQ: PTCT) was upgraded by analysts at Morgan Stanley from an "equal weight" rating to an "overweight" rating. They now have a $67.00 price target on the stock, up previously from $45.00.
Ratings data for PTCT provided by MarketBeat
PTC Therapeutics, Inc. (NASDAQ: PTCT) had its price target lowered by analysts at Cantor Fitzgerald from $80.00 to $76.00. They now have an "overweight" rating on the stock.
Ratings data for PTCT provided by MarketBeat
PTC Therapeutics, Inc. (NASDAQ: PTCT) had its price target raised by analysts at Cantor Fitzgerald from $76.00 to $113.00. They now have an "overweight" rating on the stock.
Ratings data for PTCT provided by MarketBeat
PTC Therapeutics, Inc. (NASDAQ: PTCT) was upgraded by analysts at StockNews.com from a "hold" rating to a "buy" rating.
Ratings data for PTCT provided by MarketBeat
PTC Therapeutics, Inc. (NASDAQ: PTCT) had its price target raised by analysts at Citigroup Inc. from $32.00 to $45.00. They now have a "sell" rating on the stock.
Ratings data for PTCT provided by MarketBeat
PTC Therapeutics, Inc. (NASDAQ: PTCT) had its price target raised by analysts at Royal Bank of Canada from $60.00 to $63.00. They now have an "outperform" rating on the stock.
Ratings data for PTCT provided by MarketBeat
PTC Therapeutics, Inc. (NASDAQ: PTCT) had its price target lowered by analysts at JPMorgan Chase & Co. from $74.00 to $72.00. They now have an "overweight" rating on the stock.
Ratings data for PTCT provided by MarketBeat
PTC Therapeutics, Inc. (NASDAQ: PTCT) had its "overweight" rating re-affirmed by analysts at Morgan Stanley. They now have a $70.00 price target on the stock, up previously from $67.00.
Ratings data for PTCT provided by MarketBeat
PTC Therapeutics, Inc. (NASDAQ: PTCT) had its price target raised by analysts at JPMorgan Chase & Co. from $72.00 to $78.00. They now have an "overweight" rating on the stock.
Ratings data for PTCT provided by MarketBeat
PTC Therapeutics, Inc. (NASDAQ: PTCT) had its price target lowered by analysts at JPMorgan Chase & Co. from $78.00 to $75.00. They now have an "overweight" rating on the stock.
Ratings data for PTCT provided by MarketBeat
PTC Therapeutics, Inc. (NASDAQ: PTCT) had its "outperform" rating re-affirmed by analysts at Royal Bank of Canada. They now have a $65.00 price target on the stock.
Ratings data for PTCT provided by MarketBeat
PTC Therapeutics, Inc. (NASDAQ: PTCT) had its price target lowered by analysts at JPMorgan Chase & Co. from $75.00 to $67.00. They now have an "overweight" rating on the stock.
Ratings data for PTCT provided by MarketBeat
PTC Therapeutics, Inc. (NASDAQ: PTCT) had its price target lowered by analysts at Cantor Fitzgerald from $113.00 to $112.00. They now have an "overweight" rating on the stock.
Ratings data for PTCT provided by MarketBeat
PTC Therapeutics, Inc. (NASDAQ: PTCT) had its price target raised by analysts at Royal Bank of Canada from $57.00 to $58.00. They now have an "outperform" rating on the stock.
Ratings data for PTCT provided by MarketBeat
PTC Therapeutics, Inc. (NASDAQ: PTCT) had its price target lowered by analysts at Robert W. Baird from $70.00 to $66.00. They now have an "outperform" rating on the stock.
Ratings data for PTCT provided by MarketBeat
PTC Therapeutics, Inc. (NASDAQ: PTCT) was upgraded by analysts at Bank of America Co. from a "neutral" rating to a "buy" rating. They now have a $68.00 price target on the stock.
Ratings data for PTCT provided by MarketBeat
PTC Therapeutics, Inc. (NASDAQ: PTCT) was downgraded by analysts at StockNews.com from a "strong-buy" rating to a "buy" rating.
Ratings data for PTCT provided by MarketBeat
PTC Therapeutics, Inc. (NASDAQ: PTCT) had its price target raised by analysts at Wells Fargo & Company from $68.00 to $74.00. They now have an "overweight" rating on the stock.
Ratings data for PTCT provided by MarketBeat
PTC Therapeutics, Inc. (NASDAQ: PTCT) is now covered by analysts at Truist Financial Co.. They set a "buy" rating and a $80.00 price target on the stock.
Ratings data for PTCT provided by MarketBeat
Neueste Beiträge
JPMorgan_Chase___Co_ in Amazon.com Inc. diskutieren